WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neelands, T. R.
Right arrow Articles by Macdonald, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neelands, T. R.
Right arrow Articles by Macdonald, R. L.

 Previous Article  |  Next Article 

The Journal of Neuroscience, August 15, 1999, 19(16):7057-7065

GABAA Receptors Expressed in Undifferentiated Human Teratocarcinoma NT2 Cells Differ from Those Expressed by Differentiated NT2-N Cells

Torben R. Neelands1, Jie Zhang1, and Robert L. Macdonald2, 3

1 Graduate Program in the Neurosciences and Departments of 2 Neurology and 3 Physiology, University of Michigan Health Sciences Center, Ann Arbor, Michigan 48104-1687

During CNS development, changes occur in expression of GABAA receptor subunit subtypes and GABAA receptor pharmacological and biophysical properties. We used reverse transcription PCR and whole-cell-recording techniques to determine whether GABAA receptor expression and function also changed during retinoic acid-induced differentiation of human Ntera 2 (NT2) teratocarcinoma cells into neuron-like cells (NT2-N cells). In undifferentiated NT2 cells only alpha 5, beta 3, gamma 3, and pi  subtype mRNAs were detected. NT2 GABAA receptor currents had a maximal amplitude of 52 pA and an EC50 of 4.0 µM, were relatively insensitive to enhancement by zolpidem and diazepam, and were enhanced by loreclezole and inhibited by lanthanum, zinc, and furosemide. In contrast, in NT2-N cells after 13 weeks of retinoic acid treatment, all GABAA receptor subtype mRNAs were detected. Maximal peak whole-cell currents were ~50-fold larger than NT2 cell currents, and the GABA EC50 was higher (39.7 µM). In 13 week NT2-N cells, diazepam, zolpidem, loreclezole, and lanthanum had only small effects on GABAA receptor currents, and the zinc IC50 for current inhibition was significantly higher than that for NT2 cells. In a previous study, we showed that NT2-N cells after 5 weeks of retinoic acid treatment had moderate peak currents, GABA EC50, and zinc IC50 but that currents were robustly enhanced by diazepam, zolpidem, and loreclezole. During differentiation of NT2 cells to NT2-N cells, GABAA receptors underwent changes in subunit expression and pharmacology that were similar to many of the developmental changes in GABAA receptors that occur in CNS neurons.

Key words: GABA; GABAA receptor; electrophysiology; patch clamp; RT-PCR; Ntera2; loreclezole; benzodiazepine; zinc; differentiation; NT2 cells; NT2-N cells

Copyright © 1999 Society for Neuroscience  0270-6474/99/19167057-09$05.00/0




-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-